Comment · Mon, January 6, 2025 · ND Owner
ND & Greg Doucette Partnership…
Original post in this thread
NaturalNormal9290 · 60 points
Gotta admit I was not expecting this one. Not necessarily that I’m a Greg hater, I’m just skeptical of fitness influencers that pedal the latest trend. I’m looking for to the upcoming ND pod with him on. It’ll be interesting to see the outcome. Especially, if I recall, since ND tested his products and they weren’t up to par.
What they were answering
AromaticAminoAcid · 1 points
Yeah, venture capital background is not terribly inspiring.
u/MisterYouAreSoDumb · ND Owner
It's tough, because that is how our system is set up. Our entire patent and drug approval system forces you down that path. It's much easier to make change by leveraging the realities of how a system works, rather than trying to act outside that system. Still, I have not been impressed with anyone I have met on the venture capital or startup side from a science perspective. It truly has seemed to me to be just a big group of people all trying to make as much money as possible as quickly as possible. Some of them use science buzzwords, and make it seem like they are interested in the actual science. However, the mask always seems to come off eventually. If you read into Mindstate, to me it seems like they are just trying to capitalize on the hype of things. I get why startups do that. That's how you raise capital. However, the idea of using AI to comb through online trip reports to find "next-generation" psychedelics to use as therapeutics seems just like hype riding to me. AI is the buzzword right now, just like blockchain was the buzzword five years ago. Using large language models to try and bridge the gap on our understanding of how subjective reports of certain drugs correlate to clinical outcomes might seem interesting on its surface. I also do agree with their general premise, that acute subjective experiences is a big part of whether a treatment will succeed or not. However, I am skeptical that their approach is going to do anything to bridge the gap between acute subjective trip experiences and statistically significant clinical outcomes in the existing drug models.